A guideline for the treatment and prevention of NSAID-induced ulcers

American Journal of Gastroenterology

Volumn 93, Issue 11, 1998, Pages 2037-2046

  Lanza, Frank L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; FAMOTIDINE; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; MELOXICAM; MISOPROSTOL; NITRIC OXIDE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE; SULGLICOTIDE; UNCLASSIFIED DRUG; ZINC ACEXONITE;

CLINICAL TRIAL; COLON INJURY; DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER PYLORI; HUMAN; OSTEOARTHRITIS; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SMALL INTESTINE DISEASE; STOMACH ULCER; ULCER HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; PEPTIC ULCER;

EID: 0032468069     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00588.x     Document Type: Review

References (121)

1. Cryer B., Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of non-steroidal, anti-inflammatory drug-induced damage. Arch Intern Med. 152:1992;1145-1155.
2. Soll A.H. Moderator Nonsteroidal anti-inflammatory drugs and peptic ulcer disease . Ann Intern Med. 114:1991;307-319.
3. Larkai E.N., Smith J.L., Lidsky M.D., et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastronenterol. 1987;1153-1158.
4. Bellary S.V., Isaacs P.E.T., Lee F.I. Upper gastrointestinal lesions in elderly patients presenting for endoscopy; relevance of NSAID usage. Am J Gastroenterol. 86:1991;961-964.
5. Fries J.F., Williams C.A., Bloch D.A., et al. Nonsteroidal anti-inflammatory drug-associated gastropathy Incidence and risk factor models . Am J Med. 91:1991;213-222.
6. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 115:1991;787-796.
7. Lanas A., Serrano P., Bajador E., et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 112:1997;683-689.
8. Smalley W.E., Griffin M.R. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am. 25:1996;373-396.
9. Smalley W.E., Griffin M.R., Fought R.L., et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med. 11:1996;461-469.
10. Silverstein F.E., Graham D.Y., Senior J.R., et al. 8Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs A randomized, double-blind, placebo-controlled trial . Ann Intern Med. 123:1995;241-249.
11. Lanza F.L. Double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci. 31:1986;131-136.
12. Aadland E., Fausa O., Vatn M., et al. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med. 83:1987;37-40.
13. Lanza R.L., Peace K., Gustitus L., et al. A blinded endoscopic comparative study of misoprostol vs sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol. 839:1988;143-146.
14. Lanza F.L., Fakouhi A., Rubin A., et al. A double-blind, placebo-controlled comparison of the efficacy and safety of 50 mcg, 100 mcg and 200 mcg of misoprostol, q.i.d., in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol. 84:1989;633-636.
15. Jiranek G.C., Kimmey M.D., Saunders D.R., et al. Misoprostol reduces gastroduodenal injury from one week of aspirin. An endoscopic study. Gastroenterology. 96:1989;656-661.
16. Graham D.Y., Agrawal N.M., Roth S.H. Prevention of NSAID-induced gastric ulcer with misoprostol Multicentre, double-blind placebo-controlled trial . Lancet. ii:1988;1277-1280.
17. Graham D.Y., White R.H., Moreland W., et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 119:1993;257-262.
18. Agrawal N.M., Roth S.H., Graham D.Y., et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer in randomized control trial. Ann Intern Med. 115:1991;195-200.
19. Raskin J.B., White R.H., Jackson J.E., et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers A comparison of three regimens . Ann Intern Med. 123:1995;344-350.
20. Bardhan K.D., Bjarnason I., Scott D.L., et al. The prevention and healing of acute nonsteroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol. 32:1993;990-995.
21. Elliott S.L., Yeomans N.D., Buchanan R.R., et al. Efficacy of 12 months misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol. 23:1994;171-176.
22. Raskin J.B., White R.H., Jaszewski R., et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers a prospective, double-blind, multicenter study . Am J Gastroenterol. 91:1996;223-227.
23. Koch M., Dezi A., Ferrario F., et al. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. Arch Intern Med. 156:1996;2321-2322.
24. Ekstrom P., Carling L., Wetterhus S., et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous nonsteroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol. 31:1996;753-758.
25. Hawkey C.J., Karrasch J.A., Szczepá L., et al. Omeprazole for ulcers associated with nonsteroidal anti-inflammatory drugs. N Eng J Med. 338:1998;727-734.
26. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 338:1998;719-726.
27. Ehsannulah R.S.B., Page M.C., Tildesley G., et al. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs Controlled trial of ranitidine . Br Med J. 297:1988;1017-1021.
28. Robinson M.G., Griffin J.W., Bowers J., et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 34:1989;424-428.
29. Lanza F.L. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other nonsteroidal anti-inflammatory drugs. Scand J Gastroenterol. 24:1989;24-31.
30. Cardoc-Davies T.H. Nonsteroidal anti-inflammatory drugs, arthritis and gastrointestinal bleeding in elderly patients. Age Aging. 13:1984;295-298.
31. Langman M.J.S., Morgan L., Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforation and hemorrhage. Br Med J. 290:1985;347-349.
32. Sommerville K., Faulkner G., Langham M. Nonsteroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1:1986;462-464.
33. Collier D.S.T.J., Pain J.A. Nonsteroidal anti-inflammatory drugs and peptic ulcer perforation. Gut. 26:1985;359-363.
34. Walt R., Katschinski B., Logan R., et al. Rising frequency of ulcer perforation in older people in the United Kingdom. Lancet. 1:1986;489-492.
35. Beard K., Walker A.M., Perera D.R., et al. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med. 147:1987;1621-1623.
36. Armstrong C.P., Blower A.L. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 28:1987;527-532.
37. Levy M., Miller D.R., Kaufman D.W., et al. Major upper gastrointestinal bleeding. Relation to the use of aspirin and other non-narcotic analgesics. Arch Intern Med. 148:1988;281-285.
38. Final report on the aspirin component of the ongoing health study. N Engl J Med. 321:1989;129-135.
39. Slattery J., Warlow C.P., Shorrock C.J., et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 37:1995;509-511.
40. Naschitz J.E., Yeshurun B., Odeh M., et al. Overt gastrointestinal bleeding in the course of chronic low dose aspirin administration for secondary prevention of arterial occlusive disease. Am J Gastroenterol. 85:1990;408-411.
41. Kurata J.H., Abbey D.E. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol. 12:1990;260-266.
42. Griffin M.R., Ray W.A., Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly patients. Ann Intern Med. 109:1988;359-363.
43. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly person. Ann Intern Med. 114:1991;257-263.
44. Piper J.M., Ray W.A., Daugherty J.R., et al. Corticosteroid use in peptic ulcer disease; role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 114:1991;735-740.
45. Sharr R.J., Ray W.A., Daugherty J.R., et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 153:1993;1665-1670.
46. Allison M.C., Howatson A.G., Torrance C.J., et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med. 327:1992;749-754.
47. Carson J.L., Strom B.L., Morse M.L., et al. The relative gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. Arch Intern Med. 147:1987;1054-1059.
48. Beardon P.H., Brown S.V., McDevitt T.G. Gastrointestinal events in patients prescribed nonsteroidal anti-inflammatory drugs. A controlled study using record likage in Tayside. Q J Med. 71:1989;497-505.
49. Bloom B.S. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Int J Med. 149:1989;1019-1022.
50. LaProte J.R., Carne X., Vidal X., et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and nonsteroidal anti-inflammatory drugs. Lancet. 337:1991;85-89.
51. Garcia-Rodriguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 343:1994;769-772.
52. Langman M.J.S., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 343:1994;1075-1078.
53. Henry D., Dobson A., Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin anti-inflammatory drugs. Gastroenterology. 105:1993;1078-1088.
54. Garcia Rodriguez L.A., Cattaruzzi C., Grazia Troncon M., et al. Risk of Hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other hypertensive drugs. Arch Intern Med. 158:1998;33-39.
55. Jenner P.N. A 12 month post-marketing surveillance study of nabumetone. A preliminary report. Drugs. 40:1990;38-42.
56. Stoehmann I., Fedder M., Zeidler H. German drug monitoring studies with nabumetone. Drugs. 40:1990;38-44.
57. Willkens R.F. An overview of the long-term safety experience with nabumetone. Drugs. 40:(S15):1990;34-37.
58. Benhamou C.L. Large scale open trials with etodolac (Lodine) in France An assessment of safety . Rheumatol Int. 10:(suppl):1990;29-34.
59. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflam. 10:1990;56-65.
60. Lanza F.L. Gastrointestinal toxicity of new NSAIDs. Am J Gastroenterol. 88:1993;1318-1323.
61. Roth S.H., Tindall E.A., Jain A.K., et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 153:1993;2565-2571.
62. Porro G.B., Montrone F., Petrillo M., et al. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol. 90:1995;1485-1488.
63. Roth S.H., Bennett R., Caldron P., et al. A long term endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol. 21:1994;1118-1123.
64. Chalmer T.C., Berrier J., Hewitt R., et al. Meta-analysis of randomized controlled trials as a method of estimating rare complications of nonsteroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther. 2:(supp 1):1988;9-26.
65. Scheiman J.M., Behier E.M., Loeffler K.M., et al. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci. 39:1994;97-103.
66. Levine L.R., Cloud M.L., Enas N.H. Nizatodine prevents peptic ulceration in high risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 153:1993;449-454.
67. Simon B., Muller P. Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients. Scand J Gastroenterol. 206:1994;25-28.
68. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med. 334:1996;1435-1439.
69. Hudson N., Taha A.S., Russell R.I., et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 112:1997;1817-1822.
70. ten Wolde S., Dijkmans B.A., Janssen M., et al. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther. 10:1996;347-351.
71. McCarthy D.M. Sucralfate. N Engl J Med. 325:1991;1017-1025.
72. Miglioli M., Porro G.B., Vaira D., et al. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients. Am J Gastroenterol. 91:1996;2367-2371.
73. Lanza F.L., Royer G.L., Nelson R.S. An endoscopic evaluation of the effects of aspirin, buffered aspirin and enteric-coated aspirin on the gastric and duodenal mucosa. A controlled study. N Engl J Med. 303:1980;136-138.
74. Silvoso G.R., Ivey K.J., Butt J.H., et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 91:1979;517-520.
75. Lockard O.O., Ivey K.J., Butt J.H., et al. The prevalence of duodenal lesions in patients with rheumatic disease on chronic aspirin therapy. Gastrointest Endosc. 26:1980;5-7.
76. Kelly J.P., Kaufman D.W., Jurgelon J.M. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 348:1996;1413-1416.
77. Bianchi Porro G., Montrone F., Petrillo M., et al. Sulglycotide in the prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal mucosal injury. A controlled double-blind, double-dummy, randomized endoscopic study vs. placebo in rheumatic patients. Scand J of Gastroenterol. 28:1993;875-878.
78. Rodriguez de la Serna A., Diaz-Rubio M. Multicenter clinical trial of zinc acexamate in the prevention of nonsteroidal anti-inflammatory drug induced gastroenteropathy. Spanish Study Group on NSAID-Induced Gastroenteropathy Prevention. J Rheumatol. 21:1994;927-933.
79. Huskisson E.C., Ghozian R., Kurthen R., et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol. 35:(suppl 1):1996;29-34.
80. Lanza F.L., Simon T., Quan H., et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg q.d.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg q.i.d. or ibuprofen (IBU) 800 mg t.i.d. Gastroenterology. 112:1997;A194.
81. Lanza F.L., Rack M.F., Callison D.A., et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor. Gastroenterology. 112:1997;A194.
82. Lancaster-Smith M.J., Jaderberg M.E., Jackson D.A. Ranitidine in the treatment of nonsteroidal anti-inflammatory drug associated with gastric and duodenal ulcers. Gut. 32:1991;69-75.
83. Tildesley G., Ensanullah R.S., Wood J.R. Ranitidine in the treatment of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drugs. Br J Rheumatol. 32:1993;474-478.
84. Walan A., Bader J.P., Classen M., et al. The effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 320:1989;59-75.
85. Bank S., Blumstein M., Greenberg R.E., et al. Efficacy of famotidine in the healing of active benign gastric ulceration: comparison of nonsteroidal anti-inflammatory- or aspirin-induced gastric ulcer and idiopathic gastric ulceration. Long Island Jewish Medical Center Acid-Peptic Study Group. Clinical Therapeutics. 15:1993;36-45.
86. Jaszewski R., Calzada R., Dhar R. Persistence of gastric ulcers caused by plain aspirin or nonsteroidal anti-inflammatory agents in patients treated with a combination of cimetidine, antacids and enteric-coated aspirin. Dig Dis Sci. 34:1989;1361-1364.
87. Laine L., Marin-Sorenson M., Weinsein W.M. Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol. 87:1992;1398-1402.
88. Herebach B., Raoul J.L., Bretagne J.F., et al. Helicobacter pylori A risk of severity factor of nonsteroidal anti-inflammatory drug-induced gastropathy . Gut. 33:1992;1608-1611.
89. Kim J.G., Graham D.Y. Helicobacter pylori infection and development of duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group. Am J Gastroenterol. 89:1994;203-207.
90. Goggin P.M., Collins D.A., Jazrawi R.P., et al. Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. Gut. 34:1993;1677-1680.
91. Taha A.S., Dahill S., Nakshabendi I., et al. Duodenal histology, ulceration, and Helicobacter pylori in the presence or absence of nonsteroidal anti-inflammatory drugs. Gut. 34:1993;1162-1166.
92. Li E.K., Sung J.J., Suen R., et al. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs. Scand J Rheumatol. 25:1996;42-46.
93. Bianchi Porro G., Parente F., Imbesi V., et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users. Response to omeprazole dual therapy. Gut. 39:1996;22-26.
94. Chan F.K.L., Sung J.J.Y., Chung S.C.S., et al. Randomised trial of eradication of Helicobacter pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 350:1997;975-979.
95. Cullen D.J.E., Hawkey G.M., Greenwood D.C., Humphreys H., Shepherd V., Logan R.F.A., Hawkey C.J. Peptic ulcer bleeding in the elderly Relative roles of Helicobacter pylori and nonsteroidal anti-inflammatory drugs . Gut. 41:1997;459-462.
96. Madhok R., Mackenzie J.A., Lee F.D., et al. Small bowel ulceration in patients receiving NSAIDs for rheumatoid arthritis. Q J Med. 58:1986;53-58.
97. Lang J., Price A.B., Levi A.J., et al. Diaphragm disease the pathology of nonsteroidal anti-inflammatory drug induced small intestinal strictures . J Clin Pathol. 41:1988;516-526.
98. Bjarnason I., Price A.B., Zanelli G., et al. Clinico-pathological features of NSAID induced small intestinal strictures. Gastroenterology. 94:1988;1070-1074.
99. Hershfield N.B. Endoscopic description of diaphragm disease induced by non-steroidal anti-inflammatory drugs. Gastrointest Endosc. 38:1992;267.
100. Morris A.J., Madhock R., Sturrock R.D., et al. Enteroscopic diagnosis of small bowel ulceration in patients receiving nonsteroidal anti-inflammatory drugs. Lancet. 331:1991;520.
101. Bjarnason I., Hayllar J., Macpherson A.J., et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 104:1993;1832-1847.
102. Bjarnason I., Williams P., Smethrust P., et al. The effects of NSAIDs and prostaglandins on the permeability of the human small intestine. Gut. 27:1986;1292-1297.
103. Jenkins R.T., Rooney P.J., Jones D.B., et al. Increased intestinal permeability in patients with rheumatoid arthritis A side effect of oral nonsteroidal anti-inflammatory drug therapy . Br J Rheumatol. 26:1987;103-107.
104. Reuter B.K., Davies N.M., Wallace J.L. Nonsteroidal anti-inflammatory drug enteropathy in rats role of permeability, bacteria, and enterohepatic circulation . Gastroenterology. 112:1997;109-117.
105. Bjarnason I., Williams P., So A., et al. Intestinal permeability and inflammation in rheumatoid arthritis; effects of nonsteroidal anti-inflammatory drugs. Lancet. 2:1984;1171-1174.
106. Bjarnason I., Zanelli G., Smith T., et al. Non-steroidal anti-inflammatory drug induced inflammation in humans. Gastroenterology. 93:1987;480-489.
107. Gibson G.R., Whitacre E.B., Ricotti C.A. Colitis induced by nonsteroidal anti-inflammatory drugs. Arch Intern Med. 152:1992;625-632.
108. Tanaka M., Mazzoleni G., Ridell R.H. Nonsteroidal anti-inflammatory drugs as a possible cause of collagenous colitis. Gastroenterology. 101:1991;A845.
109. Cuvelier C., Barbatis C., Mielants H., et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut. 28:1987;394-401.
110. Charuzi I., Ovnat A., Zirkin H., et al. Ibuprofen and benign cecal ulcer. J Rheumatol. 12:1985;188-189.
111. Uribe A., Johansson C., Scezak P., et al. Ulceration of the colon associated with naproxen and acetylsalicylic acid treatment. Gastrointest Endosc. 32:1986;242-244.
112. Bravo A.C., Lowman R.M. Benign ulcer of sigmoid colon. Radiology. 90:1968;113-115.
113. Walls J., Bell D., Schora W. Rectal bleeding and indomethacin. Br Med J. 1:1968;52.
114. Levy N., Gaspar E. Rectal bleeding and indomethacin suppositories. Lancet. 305:1975;577.
115. Lanthier P., Detry R., Debongnie J.C., et al. Solitary rectal lesions due to suppositories containing acetylsalicylic acid and paracetamol. Gastroentrol Clin Biol. 11:1987;250-253.
116. Wilson R.G., Smith A.N., MacIntyre I.M.C. Complications of diverticular disease and nonsteroidal anti-inflammatory drugs. A prospective study. Br J Surg. 77:1990;1103-1104.
117. Campbell K., Steele R.J.C. Non-steroidal anti-inflammatory drugs and complicated diverticular disease; a case-control study. Br J Surg. 78:1991;190-191.
118. Foutch P.G. Diverticular bleeding Are nonsteroidal anti-inflammatory drugs risk factors for hemorrhage and can colonoscopy predict outcome for patients? Am J Gastroenterol. 90:1995;1779-1784.
119. Kaufman H.J., Taubin H.L. NSAID activate quiescent inflammatory bowel disease. Ann Intern Med. 107:1987;513-516.
120. Rampton D.S., McNeil N.I., Sarner M. Analgesic ingestion and other factors preceeding relapse in ulcerative colitis. Gut. 24:1983;187-189.
121. Evans J.M.M., McMahon A.D., Murray F.E., et al. Nonsteroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 40:1997;619-622.